orbsen – Orbsen Therapeutics

31 01, 2023

Orbsen Therapeutics announces encouraging interim results from the NEPHSTROM proof of concept clinical study evaluating ORBCEL™ cell therapy in patients with diabetes and advanced chronic kidney disease

orbsen2024-06-13T16:52:41+00:00January 31st, 2023|

GALWAY, Ireland, Jan. 26, 2023 /PRNewswire/ -- Orbsen Therapeutics Limited ("Orbsen"), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). NEPHSTROM is a randomized, double-blind, placebo-controlled Phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone [...]

9 02, 2021

Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says

orbsen2024-06-13T16:52:41+00:00February 9th, 2021|

Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says Published Date:20 Apr 2020 Phase IIb could include COVID-19 focus depending on results Orbsen in talks with and open to CMOs to manage downstream manufacturing [...]

8 04, 2020

Orbsen Therapeutics Launches Clinical Trial to Address Leading Cause of Death Among COVID-19 Patients

orbsen2024-06-13T16:52:42+00:00April 8th, 2020|

GALWAY, Ireland, April 8, 2020 /PRNewswire/ -- Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of best-in-class stromal cell immunotherapies, announced the beginning of a phase 2a clinical trial for the treatment of COVID-19 patients with acute respiratory distress syndrome (ARDS). Nearly 90 percent of deaths caused by COVID-19 are the result of ARDS.

1 07, 2019

Minister opens new Business Innovation Centre for life sciences start-ups

orbsen2024-06-13T16:52:42+00:00July 1st, 2019|

The new development complements the University’s existing Business Innovation Centres which are home to 52 early-stage companies. The University’s focus with the new Business Innovation Centre – North at Dangan Business Park is in driving Life Sciences research and innovation to develop services and solutions that demonstrably improve outcomes for patients through solutions that save [...]

9 04, 2019

Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for two Autoimmune Liver Diseases

orbsen2024-06-13T16:52:42+00:00April 9th, 2019|

Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of first-in-class stromal cell immunotherapies, announced its second generation immunotherapy ORBCEL-C™ is being administered to patients participating in MERLIN, a multi-site United Kingdom-based clinical trial to determine the therapy’s safety and effectiveness in treating two types of chronic autoimmune liver diseases. “Orbsen’s product [...]

2 04, 2019

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland

orbsen2024-06-13T16:52:42+00:00April 2nd, 2019|

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland Progress in company’s product pipeline requires move to larger facilities (2 April 2019) Galway, Ireland — Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced it will move its base of operations from the National University [...]

2 10, 2018

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations

orbsen2024-06-13T16:52:42+00:00October 2nd, 2018|

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations Patients with diabetic kidney disease are being treated with a breakthrough stromal cell immunotherapy (October 2, 2018) Galway, Ireland — Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation [...]

1 05, 2018

Galway Based Orbsen Therapeutics Announces It’s Part of Consortium Awarded a Grant from UK Government’s Innovate UK Program

orbsen2024-06-13T16:52:42+00:00May 1st, 2018|

NEW YORK–(BUSINESS WIRE)–Orbsen Therapeutics Limited, a leading immunotherapy company focused on the development of cell therapies for diabetic and autoimmune diseases has announced that it is part of a consortium awarded a UKE7M grant from the UK Government’s Innovate UK program. […]

22 02, 2018

Irish Times Features

orbsen2024-06-13T16:52:42+00:00February 22nd, 2018|

NUI Galway leads stem-cell research on diabetic kidney disease, €1.7m in funding for twenty new high-potential research projects announced, Scientific research projects get €1.7million funding boost, Orbsen Therapeutics to take part in €6m liver disease clinical trial, Innovation Awards profile: Orbsen Therapeutics – Stem cell research, The cream of start-ups, college spin-offs and smooth operators. […]

22 02, 2018

Dr. Larry Couture Named CEO Of Orbsen Therapeutics

orbsen2024-06-13T16:52:42+00:00February 22nd, 2018|

NEW YORK, Sept. 6, 2016 /PRNewswire/ — Dr. Jack Kavanaugh, Chairman of Orbsen Therapeutics (http://www.orbsentherapeutics.com/), announced today the appointment of Larry Couture, PhD, as CEO. “Dr. Couture brings a remarkable background in cellular and genetic therapeutics with industry leading experience in both the scientific and business development of leading edge therapeutics,” said Kavanaugh. He added, “His industry experience at [...]

About orbsen